16
Jan
2012
Posted in I - Series C, Q - 3Q11, R - ROCKY MOUNTAIN, X - BioAcrylic, X - Biofuel, XX - CO
OPX Biotechnologies (Boulder, CO) a development-stage biofuels company using synthetic biology to engineer the microbes as a bio-acrylic renewable fuel source, closed a $36.5M Series C financing. Participants include US Renewables Group, DBL Investors, Mohr Davidow Ventures, Braemar Energy Ventures, Altira Group and X/Seed Capital.
Thanx for your patience as we catch-up.
08
Nov
2011
08
Nov
2011
08
Nov
2011
28
Mar
2011
Posted in I - Series A, Q - 1Q11, R - ROCKY MOUNTAIN, X - Inflammation, X - Pain, XX - CO
PanTheryx (Boulder, CO) a commercial-stage pharmaceutical company focused on the acquisition, development and commercialization of pain, inflammation, GERD, rhinitis and peripheral neuropathy products for the Indian healthcare market, closed a $1M Series A financing. Participants were not identified.
03
Jan
2011
Posted in I - Series D, Q - 4Q10, R - ROCKY MOUNTAIN, X - Alzheimer's, X - Medical Food, XX - CO
Accera (Broomfield, CO) a commercial-stage biotechnology company that developed and markets Axona for the dietary management of metabolic processes associated with mild to moderate Alzheimer’s disease, closed a $11M Series D financing. Participants were not identified, prior investors have include Inventages Venture Capital, POSCO BioVentures and Bloodstone Ventures.
11
Nov
2010
Posted in I - Series C, Q - 4Q10, R - ROCKY MOUNTAIN, X - Device (Diagnostic), X - Oncology, XX - CO
Biodesix (Broomfield, CO) a commercial-stage personalized medicine company focused on diagnostic products that inform treatment decisions and patient care, whose initial product, VeriStrat, predicts response to the targeted therapy erlotinib in patients with advanced NSCLC, closed a $7.1M Series C financing. Participants were not identified.
20
Oct
2010
Posted in I - Series D, Q - 3Q10, R - WEST, X - Oncology, XX - CO
Cylene Pharmaceuticals (San Diego, CA) a clinical-stage small molecule company focused on multiple myeloma, closed a $12M Series D financing. Participants include Sanderling Ventures, HBM BioVentures, Novartis Venture Fund, BioVentures Investors, Lilly Ventures, Mitsui & Co. and Morningside Venture Investments.
12
Jul
2010
Posted in I - Series B, Q - 2Q10, R - ROCKY MOUNTAIN, X - Asthma, X - COPD, X - IBD, XX - CO
N30 Pharma (Boulder, CO) a preclinical-stage biopharmaceutical company focused on small molecules inhibting GSNOR for the potential treatment of asthma, COPD, inflammatory bowel disease and heart failure, closed a $10M Series B financing. Participants include Deerfield Management, Tiger Management, Bridger Capital and Swift Current Partners.
12
Apr
2010
Posted in I - Series E, Q - 1Q10, R - ROCKY MOUNTAIN, X - Hepatitis C, X - Oncology, X - Vaccines, XX - CO
GlobeImmune (Lousiville, CO) a clinical-stage biopharmaceutical company developing a therapeutic vaccine platform focused on pancreatic cancer and hepatitis C, Closed a $17.5M Series E financing. Participants include Generali Financial Holding, BSI, Celgene, Wexford Capital, Mellon Family Investment Company, Eminent Venture Capital, Boston Life Science Venture, WRF Capital, Partners Healthcare, Yasuda, Genentech, Biogen Idec, CIDC, PAC-LINK [...]
15
Sep
2009
Posted in I - Series E, Q - 3Q09, R - SOUTH EAST, X - Device (Temp Mgmt.), XX - CO
Medivance (Louisville, KY) a commercial-stage device company focused on non-invasive core temperature management, closed a $8.1M Series E financing. Participants include Quellos Private Capital, MDY Healthcare, Cross Atlantic Partners, Skyline Ventures, Camden Partners, Partisan Management Group, Nikko Synergy Ventures, Kimberly-Clark, CSFB Private Equity and New England Capital Partners.
22
May
2009
Posted in I - Series A, Q - 2Q09, R - ROCKY MOUNTAIN, X - Oncology, XX - CO
Clovis Oncology (Boulder, CO) an entity focused on licensing or acquiring rights to oncology compounds in all stages of clinical development, closed a $145M Series A financing. Participants include Domain Associates, New Enterprise Associates, Versant Ventures, Aberdare Ventures, Abingworth, Frazier Healthcare Ventures, and ProQuest Investments.
26
Apr
2009
Posted in I - Series B, Q - 2Q09, R - ROCKY MOUNTAIN, X - Biofuel, X - Metabolism, XX - CO
OPX Biotechnologies (Boulder, CO) a research-stage biofuels company using synthetic biology to engineer the microbes as a renewable fuel source, added to their Series B financing bringing the round up to $17.5M. Participants include Braemar Energy Ventures, Altira Group, Mohr Davidow Ventures and X/Seed Capital.